Lee Gary K. 4
4 · Lyell Immunopharma, Inc. · Filed Feb 28, 2023
Insider Transaction Report
Form 4
Lee Gary K.
Chief Scientific Officer
Transactions
- Award
Option (right to buy)
2023-02-24+600,000→ 600,000 totalExercise: $2.13Exp: 2033-02-23→ Common Stock (600,000 underlying)
Holdings
- 4,702
Common Stock
Footnotes (2)
- [F1]Shares acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan.
- [F2]12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months.